Glendale, AZNCT05412927Now EnrollingIRB Ready

Acute Coronary Syndrome Clinical Trial in Glendale, AZ

Access cutting-edge acute coronary syndrome treatment through this clinical trial at a research site in Glendale. Study-provided care at no cost to qualified participants.

Sponsored by Angel Medical Systems

Quick Self-Assessment

See if you qualify for this Glendale location

Preparing your pre-screening questions…

Expert Care in Glendale

Access acute coronary syndrome specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related acute coronary syndrome treatment provided free

Apply for This Glendale Location

Check if you qualify for this acute coronary syndrome clinical trial in Glendale, AZ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Glendale

    Convenient for AZ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Glendale site if eligible
  4. 4Begin participation

About This Acute Coronary Syndrome Study in Glendale

500 Patients (minimum) will be enrolled following commercial implant. Will be treated by their physicians using the standard of care. Standard of care for the Guardian includes an in-office initial programming visit 7-14 days following implant and every 6 months.

Sponsor: Angel Medical Systems

Who Can Participate

Inclusion Criteria

1\. Subject has at least one of the following conditions:
Diabetes (Type I or Type II)
Compromised renal function (Cr \> 1.2 mg/dl or creatinine clearance less than 50)
TIMI Risk Score of at least 3 2\. Previously diagnosed with a high-risk acute coronary syndrome (e.g., Unstable Angina, STEMI or NSTEMI) or has undergone or is scheduled for CABG within 6 months of implantation. 3\. Has already undergone coronary angiography and revascularization, unless the physician determines it is appropriate to implant before or during the planned procedure. 4\. Lives in a geographic area in close proximity (within approximately 60 minutes by EMS) to any hospital that can treat AMI. 5\. Subjects (men or women) at least 21 years of age. Women of childbearing age must have a negative pregnancy test or confirmation of one of the following: <!-- -->
Post-menopause or amenorrhoeic during the past year
Surgical sterilization
Use of effective contraceptive method

Exclusion Criteria

1\. In the investigator's opinion, subject lacks ability to respond appropriately to alarms, e.g., illiteracy, poor memory or cognitive function, dementia or other condition affecting memory function, etc. 2\. There is known compromised tissue at the site of lead implantation in the apex of the right ventricle, e.g., prior infarct affecting the RV apex location. 3\. A permanent pacemaker or ICD is already in place or the subject is indicated for ICD or pacemaker implantation based on the guidelines published by the American College of Cardiology as Class I and IIa recommendations. Class IIb recommendations are at the investigator's discretion. 4\. Subject cannot feel the IMD vibration when placed on top of the skin on the left pectoral side of the chest. 5\. Subject has recurrent or persistent atrial fibrillation. 6. Subject has recurrent or persistent non-sinus cardiac rhythm, second or third degree atrioventricular blocks, QRS duration greater than 120 ms, Benign Early Repolarization (BER), Brugada Syndrome (LLB, BBB, RBB) or Rate Induced BBB. 7\. Subject has left ventricular hypertrophy evidenced by EKG criteria. 8. Subject has any condition preventing the subcutaneous implantation of the Guardian® System in a left pectoral pouch, such as: superior vena cava thrombosis, subcutaneous tissue deemed inappropriate for the procedure or prior central venous access via portacath, Hickman, Groshong, or similar placed in a left pectoral location or left side PICC line. 9\. Subject has extremely heavy alcohol consumption (participates in binge drinking that leads to alcohol intoxication) or has history of alcohol or illicit drug abuse within past 5 years. 10\. There is evidence of unresolved infection (fever \> 38o C and/or leukocytosis \> 15,000). 11\. Subject has history of bleeding disorders or severe coagulopathy (platelets \< 100,000 plts/ml; APTT or PT \> 1.3 x reference range). 12\. Subject has had a hemorrhagic stroke or transient ischemic attack (TIA) in the past 6 months. 13\. Subject has a potentially fatal disease, such as cancer or refractory congestive heart failure, associated with limitation of life expectancy, which may lead to inadequate compliance to the protocol or confusing data interpretation. 14\. Subject has clinical conditions such as heart diseases, difficult-to-control blood pressure, difficult-to-control insulin-dependent diabetes or serious prior infections attributed to the diabetes, or others that, at the investigator's discretion, could seriously affect the subject's current clinical condition during study procedures. 15\. Subject has previously been implanted with an AngelMed Guardian® System, current participation or previous participation in another drug or device study in the past 30 days that conflicts with this study as determined by the study sponsor. 16\. Subject has experienced gastro-intestinal hemorrhage in the past 6 months. 17. Subject has any situation in which the use of aspirin is contraindicated for at least 6 months. 18\. Subject has epilepsy. 19. Subject has known severe allergies, e.g., peanut, bee sting, etc. 20. Subject has a known coronary occlusion that cannot be reperfused e.g. known multiple small vessel disease, saphenous vein graft, prior angiography where doctor could not intervene, or jailed occlusion.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Glendale?

Yes, this clinical trial (NCT05412927) has an active research site in Glendale, AZ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Acute Coronary Syndrome Treatment Options in Glendale, AZ

If you're searching for acute coronary syndrome treatment options in Glendale, AZ, this clinical trial (NCT05412927) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Glendale research site is actively enrolling participants for this clinical trial. You'll receive care from experienced acute coronary syndrome specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all acute coronary syndrome clinical trials near you to find additional studies recruiting in your area.

More Heart Attack Trials in Glendale, AZ

See all heart attack clinical trials recruiting in Glendale — not just this study.

Browse Heart Attack Trials in Glendale →

Browse More Trials by Condition

Heart Attack TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Glendale?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Glendale, AZ